ISSN: 2278-0238

Internationale Zeitschrift für Forschung und Entwicklung in Pharmazie und Biowissenschaften

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Abstrakt

Antimalarial drug discovery and development: Issues and prospects

Dipak Chetia

There was no significant progress in the reduction of malaria cases globally during the period 2015-2017 as per the latest epidemiological report (WHO, Malaria Report 2018). The malaria affected countries mainly rely on Artemisinin-based Combination Therapy (ACT) as no new drug has been discovered during the last couple of years. Therefore, the discovery of new antimalarial drugs to target the parasite at various stages of its life cycle is an urgent necessity to address the current stagnant therapeutic situation as well as to fight against the rapidly emerging resistant strains of the malaria parasites. The objective of the presentation is to highlight the achievements and shortcomings, possibilities of working on new areas for development of potent antimalarial drugs, problems and issues in the screening of antimalarial compounds, necessity for development of easy, affordable and fast screening method. Salient points related to current status and possible newer research targets to be taken into consideration for antimalarial drug discovery and development shall be systematically discussed and deliberated (Figure 1). The prime target of currently used antimalarial drugs is the erythrocytic stage of the parasite and except few, others show very less therapeutic efficacy individually. Additionally, most of these drugs are not effective against resistant malaria. Potent antimalarial drug candidates based on novel targets need to be developed not only for erythrocytic stage but also to target the parasite at other stages which may work by different mechanism of action against the parasites. There is a need for developing easier, affordable and fast screening method to enable more medicinal chemists to involve in the new antimalarial drug discovery and development programmes. The development of most effective and long acting chemicals/ drugs for malaria intervention is equally important in the control of malaria.